Thyroid Disease in Children, Pregnancy, Older Adults, Athletes, and Type 2 Diabetes

Thyroid Disease in Children: What Parents and Clinicians Must Know

Thyroid disorders in children carry stakes that adults simply do not face: every week of untreated hypothyroidism during the first three years of life risks permanent cognitive impairment. Congenital hypothyroidism (CH) affects approximately 1 in 3,000 newborns in the United States and is one of the most common preventable causes of intellectual disability [1]. Newborn screening programs, mandated in all 50 U.S. states, detect elevated TSH on dried blood spots collected at 24 to 48 hours of life, making early intervention possible [2].

When CH is confirmed, levothyroxine should start within 2 weeks of birth. The recommended starting dose is 10 to 15 mcg/kg/day, titrated to keep serum T4 in the upper half of the normal range and TSH below 5 mIU/L during the first year [3]. The goal is not merely biochemical normalization. A landmark follow-up from the New England Congenital Hypothyroidism Collaborative found that children treated within the first month of life scored significantly higher on IQ testing at age 7 compared to those treated later [4].

Acquired hypothyroidism in school-age children is most often autoimmune (Hashimoto thyroiditis), accounting for over 70% of pediatric hypothyroidism cases beyond infancy [5]. Symptoms include growth deceleration, delayed bone age, fatigue, and constipation. A child whose height velocity drops by more than 1 standard deviation per year warrants thyroid function testing even without obvious goiter. Pediatric Graves disease, the leading cause of hyperthyroidism in children, affects approximately 1 in 5,000 children per year, with girls outnumbering boys 5:1 [6]. Methimazole (not propylthiouracil, due to hepatotoxicity risk in children) is the first-line antithyroid medication at an initial dose of 0.2 to 0.5 mg/kg/day [7].

Subclinical hypothyroidism (TSH 4.5, 10 mIU/L with normal free T4) in children remains a subject of clinical debate. The 2022 European Thyroid Association guidelines recommend against routine levothyroxine treatment in children with TSH below 10 mIU/L unless growth impairment, learning difficulties, or symptoms are present [8]. Watchful waiting with repeat TSH testing at 3 to 6 months is appropriate for most mild cases.

Thyroid Disease in Pregnancy: Narrow TSH Targets Protect Two Patients

Pregnancy narrows the acceptable TSH range considerably. The American Thyroid Association (ATA) 2017 guidelines specify a first-trimester TSH target of <2.5 mIU/L for women already on levothyroxine, and many clinicians apply the same threshold to newly diagnosed hypothyroidism in pregnancy [9]. The reason is straightforward: the fetal thyroid does not produce its own hormone until approximately weeks 10, 12, meaning the developing brain depends entirely on maternal thyroid hormone during this window [10].

Overt hypothyroidism in pregnancy, defined as elevated TSH with low free T4, is associated with a 2- to 3-fold increase in risk of placental abruption, preterm birth, and neurodevelopmental delay [11]. The CATS (Controlled Anoxia and Thyroid Screening) trial, published in the New England Journal of Medicine, found that universal screening and treatment of subclinical hypothyroidism did not improve child cognitive outcomes at age 5, but the trial has been criticized for late gestational age at treatment initiation (median 13.3 weeks), which may have missed the critical first-trimester window [12].

Women who are euthyroid before conception should have TSH checked as soon as pregnancy is confirmed. Women already taking levothyroxine typically require a 25 to 30% dose increase in the first trimester because pregnancy increases thyroxine-binding globulin, expands plasma volume, and accelerates T4 metabolism [13]. A practical approach: instruct the patient to add two extra levothyroxine tablets per week immediately upon a positive home pregnancy test, then confirm with TSH measurement at 4 to 6 weeks gestation [9].

Postpartum thyroiditis affects 5 to 10% of women within the first year after delivery [14]. It follows a classic pattern: transient hyperthyroidism at 1 to 4 months, followed by hypothyroidism at 4 to 8 months, with spontaneous resolution in most cases. Women with thyroid peroxidase (TPO) antibodies have a 3-fold higher risk of postpartum thyroiditis [14]. Those who remain hypothyroid at 12 months have a 50% chance of permanent hypothyroidism within 7 years and require ongoing monitoring [15].

Gestational hyperthyroidism from human chorionic gonadotropin (hCG) stimulation is a separate entity from Graves disease and typically resolves by the second trimester without antithyroid drugs. Graves disease in pregnancy requires methimazole after the first trimester (propylthiouracil is preferred in the first trimester due to methimazole embryopathy risk), targeting free T4 in the high-normal range while avoiding fetal hypothyroidism [9].

Thyroid Disease in Older Adults: Higher TSH Thresholds and Lower Treatment Urgency

TSH naturally rises with age. Adults over 80 have a median TSH approximately 0.5 mIU/L higher than younger adults, and population data from the National Health and Nutrition Examination Survey (NHANES III) confirm that 4 to 8% of women over 60 have subclinical hypothyroidism [16]. Not all of it requires treatment. The ATA and the American Association of Clinical Endocrinology both recognize that a TSH of 6, 7 mIU/L in an 80-year-old may represent normal physiological aging rather than thyroid pathology [17].

The TRUST trial (Thyroid Hormone Replacement for Subclinical Hypothyroidism in Older Adults), a randomized, double-blind, placebo-controlled study of 737 adults aged 65 and older with subclinical hypothyroidism (median TSH 6.4 mIU/L), found no benefit from levothyroxine on thyroid-related symptoms, tiredness, or quality of life compared to placebo at 1 year [18]. As guideline author Dr. David Pearce stated in the TRUST publication, "Routine levothyroxine treatment for subclinical hypothyroidism should not be offered to older adults without careful individual assessment" [18].

Subclinical hyperthyroidism in older adults carries more clinical urgency. TSH below 0.1 mIU/L is independently associated with a 3-fold increase in atrial fibrillation risk [19] and accelerated bone loss, particularly at the femoral neck. The AACE/ATA guidelines recommend treating TSH persistently below 0.1 mIU/L in adults over 65, given the cardiac and skeletal risks [17]. Options include methimazole, radioactive iodine, or thyroidectomy depending on the underlying cause.

Medication interactions deserve special attention in older patients. Levothyroxine absorption is reduced by calcium carbonate, ferrous sulfate, proton pump inhibitors, and cholestyramine, all of which are commonly prescribed in this age group [20]. Separating levothyroxine from these agents by at least 4 hours is the standard recommendation, though liquid formulations or soft-gel capsules may partially circumvent absorption interference [20].

Thyroid Disease in Athletes: Performance Consequences and Testing Pitfalls

Even mild thyroid dysfunction measurably impairs athletic performance. Hypothyroidism reduces mitochondrial oxidative capacity, decreases cardiac output at peak exercise, and lowers erythropoietin production, all of which translate to lower VO2 max and faster glycogen depletion [21]. A study in the Journal of Clinical Endocrinology and Metabolism found that hypothyroid patients showed a 15 to 20% reduction in maximal aerobic capacity that normalized within 12 weeks of adequate levothyroxine replacement [22].

The diagnostic challenge in athletes is that intense endurance training suppresses TSH transiently and lowers total T3 via the "low T3 syndrome" or euthyroid sick syndrome. In a study of 117 elite endurance athletes, 28% had free T3 below the population reference range, despite normal TSH and free T4 [23]. This pattern does not represent true hypothyroidism and does not respond to levothyroxine. Treatment thresholds in athletes should match general population criteria: overt hypothyroidism (elevated TSH with low free T4) requires treatment; isolated low free T3 with normal TSH does not [24].

Graves disease and autoimmune hyperthyroidism can mimic overtraining syndrome. Weight loss despite adequate caloric intake, resting tachycardia, heat intolerance, and declining performance despite a reduced training load should prompt TSH measurement. Methimazole-treated hyperthyroid athletes may compete if TSH is controlled, but beta-blockers used for symptom management are banned in many precision and shooting sports under World Anti-Doping Agency (WADA) regulations [25].

Levothyroxine is not on the WADA prohibited list. However, its use in euthyroid athletes for purported performance enhancement lacks evidence and risks iatrogenic hyperthyroidism with its attendant cardiac arrhythmia and bone density risks [25].

Thyroid Disease and Type 2 Diabetes: A Bidirectional Hormonal Relationship

Thyroid dysfunction and type 2 diabetes coexist more often than chance alone predicts. A cross-sectional analysis of 6,288 patients with type 2 diabetes found that 13.4% had some form of thyroid disease, compared to 6.6% in controls without diabetes [26]. The relationship runs in both directions. Insulin resistance accelerates Hashimoto thyroiditis progression in genetically susceptible individuals, and hypothyroidism directly worsens insulin sensitivity by reducing glucose transporter-4 (GLUT-4) expression in muscle cells [27].

Hypothyroidism also raises LDL cholesterol by 10 to 20 mg/dL, triglycerides by 20 to 30%, and increases cardiovascular risk at a time when patients with type 2 diabetes are already managing dyslipidemia aggressively [28]. Statin therapy partially corrects this lipid profile, but adequately treating hypothyroidism first produces independent and additive benefit. The ADA Standards of Medical Care in Diabetes recommend TSH screening at diagnosis in all patients with type 2 diabetes, given the high co-occurrence rate [29].

GLP-1 receptor agonists, now first-line therapy in many patients with type 2 diabetes and cardiovascular disease, interact with thyroid biology in ways that warrant attention. Semaglutide and liraglutide carry an FDA black box warning for medullary thyroid carcinoma (MTC) risk based on rodent data. Human data from the LEADER trial (N=9,340) and SUSTAIN-6 trial (N=3,297) did not show increased MTC incidence, but patients with a personal or family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN2) should not receive these agents [30]. The FDA label specifies that clinicians should counsel all patients on MTC symptoms before initiating GLP-1 therapy [31].

Metformin, the most widely used first-line agent for type 2 diabetes, does not alter thyroid function tests in euthyroid patients. In patients with hypothyroidism on levothyroxine, however, metformin has been associated with a modest TSH reduction (approximately 0.2, 0.4 mIU/L) without clinical consequences in most cases, though the mechanism remains under investigation [32]. Monitoring TSH annually in patients on both medications is appropriate standard practice.

Hyperthyroidism in type 2 diabetes creates a separate management challenge. Elevated thyroid hormone accelerates hepatic glucose production and increases intestinal glucose absorption, raising fasting and postprandial glucose by a clinically meaningful margin. Patients who present with unexplained deterioration in glycemic control, particularly with weight loss and palpitations, should have TSH measured before adjusting diabetes medications. Treating the hyperthyroidism frequently normalizes glucose without any change to the diabetes regimen [27].

Diagnosing Thyroid Disease Across Populations: Which Tests, Which Reference Ranges

A single TSH measurement is the appropriate first-line test in all five populations discussed here, with free T4 added if TSH is outside the reference range [33]. The standard adult reference range of 0.45, 4.5 mIU/L requires adjustment for trimester in pregnancy and cautious interpretation in older adults, as noted above. Children have a higher normal TSH upper limit: neonates may have TSH up to 20 mIU/L in the first 48 hours; by age 6 months the range narrows to approximately 0.6, 5.5 mIU/L [3].

Thyroid peroxidase (TPO) antibodies should be checked whenever autoimmune thyroid disease is suspected: in children with goiter or growth delay, in pregnant women with a family history of thyroid disease, in older adults with unexplained fatigue, and in patients with type 2 diabetes at diagnosis [9]. TPO positivity in a euthyroid patient predicts progression to overt hypothyroidism at a rate of approximately 4.3% per year and justifies TSH monitoring every 12 months rather than every 5 years [34].

Thyroid ultrasound adds anatomic detail but does not replace biochemical testing for function assessment. In children with a palpable goiter or nodule, ultrasound should precede any decision about fine-needle aspiration, given the lower malignancy rate in pediatric thyroid nodules (approximately 5 to 15%) compared to adults (approximately 7 to 15% with higher differentiated cancer prevalence) [35].

Levothyroxine Dosing Across Populations: Getting the Numbers Right

Dosing is not one-size-fits-all. Infants with confirmed congenital hypothyroidism start at 10 to 15 mcg/kg/day. Older children require approximately 4 to 6 mcg/kg/day. Adolescents approach the adult replacement dose of 1.6 mcg/kg/day, which is also the standard starting point in otherwise healthy adults with overt hypothyroidism [36].

Pregnant women already on levothyroxine need a 25 to 30% dose increase in the first trimester, as noted above, with TSH rechecked every 4 weeks through 20 weeks gestation, then once at 26 to 28 weeks [9]. Older adults with cardiovascular disease or prolonged hypothyroidism should start at a lower dose of 12.5 to 25 mcg/day and titrate slowly over 6 to 8 weeks to avoid precipitating angina or arrhythmia [37].

Generic levothyroxine and brand-name Synthroid are bioequivalent by FDA standards, but switching between formulations can shift TSH by 0.5, 1.0 mIU/L in sensitive patients [38]. The Endocrine Society recommends that patients remain on the same formulation once stabilized, and that TSH be rechecked 6 to 8 weeks after any formulation change [36].